Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Eidos Therapeutics, Inc. (EIDX)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Sep-30-20 | Jun-30-20 | Mar-31-20 | Dec-31-19 | Sep-30-19 | Jun-30-19 | Mar-31-19 | Dec-31-18 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Total revenues | 0.1 | 0.0 | 0.0 | 0.0 | 26.7 | 0.0 | 0.0 | 0.0 |
| Revenue growth | -99.5% | | | | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 2.5 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.1 | 0.0 | 0.0 | 0.0 | 24.2 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | | | | 90.6% | | | |
| Selling, general and administrative [+] | 7.0 | 10.3 | 5.3 | 5.5 | 6.0 | 2.3 | 4.0 | 2.4 |
| General and administrative | 7.0 | 10.3 | 5.3 | 5.5 | 6.0 | 2.3 | 4.0 | 2.4 |
| Research and development | 22.6 | 17.9 | 17.6 | 13.9 | 12.0 | 12.5 | 8.5 | 8.3 |
| EBITDA [+] | -29.3 | -28.1 | -22.9 | -19.3 | 6.3 | -14.8 | -12.6 | -10.7 |
| EBITDA growth | -567.7% | 90.1% | 81.9% | 80.6% | -157.2% | 83.0% | 57.4% | 109.2% |
| EBITDA margin | -23092.9% | | | | 23.5% | | | |
| Depreciation and amortization | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT [+] | -29.4 | -28.2 | -22.9 | -19.3 | 6.3 | -14.8 | -12.6 | -10.7 |
| EBIT growth | -570.4% | 90.9% | 81.9% | 80.5% | -156.9% | 82.9% | 57.4% | 109.5% |
| EBIT margin | -23152.0% | | | | 23.4% | | | |
| Interest expense | 0.8 | 0.6 | 0.5 | 0.3 | | | | 1.0 |
| Interest expense | 0.8 | 0.6 | 0.5 | 0.3 | | | | 1.0 |
| Other income (expense), net [+] | 0.0 | 0.0 | 0.6 | 0.7 | 0.7 | 0.7 | 0.9 | 1.9 |
| Other | 0.0 | 0.0 | 0.6 | 0.7 | 0.7 | 0.7 | 0.9 | 1.9 |
| Pre-tax income | -30.2 | -28.8 | -22.8 | -19.0 | 6.9 | -14.1 | -11.7 | -9.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -30.2 | -28.8 | -22.8 | -19.0 | 6.9 | -14.1 | -11.7 | -8.9 |
| Net margin | -23760.6% | | | | 26.0% | | | |
| |
| Basic EPS [+] | ($0.79) | ($0.75) | ($0.60) | ($0.52) | $0.19 | ($0.39) | ($0.32) | ($0.42) |
| Growth | -514.9% | 94.7% | 85.1% | 23.8% | -164.2% | -72.4% | -82.1% | -70.6% |
| Diluted EPS [+] | ($0.79) | ($0.75) | ($0.60) | ($0.51) | $0.18 | ($0.38) | ($0.32) | ($0.41) |
| Growth | -527.7% | 96.2% | 86.6% | 26.0% | -162.3% | -69.9% | -79.2% | -65.7% |
| |
| Shares outstanding (basic) [+] | 38.4 | 38.3 | 38.0 | 36.6 | 36.6 | 36.3 | 36.2 | 21.4 |
| Growth | 4.9% | 5.5% | 5.1% | 71.4% | 1.7% | 347.7% | 723.6% | 494.1% |
| Shares outstanding (diluted) [+] | 38.4 | 38.5 | 38.3 | 37.1 | 37.7 | 36.8 | 36.8 | 22.0 |
| Growth | 1.8% | 4.6% | 4.2% | 68.4% | 4.9% | 310.5% | 608.4% | 409.6% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|